Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

References

• Ahmadian G, Randhawa JS, Easton AJ. Expression of the ORF-2 protein of the human respiratory syncytial virus M2 gene is initiated by a ribosomal termination-dependent reinitiation mechanism. EMBO J.19(11), 2681–2689 (2000).
   PubMed Web of Science ®Google Scholar
• Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology344(2), 328–339 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott J, Lynch OT, Suessmuth Y et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin–Cullin E3 ligase. J. Virol.81(7), 3428–3436 (2007).
   PubMed Web of Science ®Google Scholar
• Tran KC, He B, Teng MN. Replacement of the respiratory syncytial virus nonstructural proteins NS1 and NS2 by the V protein of parainfluenza virus 5. Virology368(1), 73–82 (2007).
   PubMed Web of Science ®Google Scholar
• Lo MS, Brazas RM, Holtzman MJ. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of STAT2 expression and α/β interferon responsiveness. J. Virol.79(14), 9315–9319 (2005).
   PubMed Web of Science ®Google Scholar
• Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. Suppression of the induction of α, β, and λ interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J. Virol.78(8), 4363–4369 (2004).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Madhi SA et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis.193(4), 573–581 (2006).
   PubMed Web of Science ®Google Scholar
• Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Virol.74(14), 6442–6447 (2000).
   PubMed Web of Science ®Google Scholar
• Hallak LK, Spillmann D, Collins PL, Peeples ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Virol.74(22), 10508–10513 (2000).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol.2(8), 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol.176(3), 1600–1608 (2006).
   PubMed Web of Science ®Google Scholar
• Harcourt JL, Karron RA, Tripp RA. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C–CX3CR1 binding and leukocyte chemotaxis. J. Infect. Dis.190(11), 1936–1940 (2004).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol.77(11), 6580–6584 (2003).
   PubMed Web of Science ®Google Scholar
• Amanatidou V, Sourvinos G, Apostolakis S, Tsilimigaki A, Spandidos DA. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr. Infect. Dis. J.25(5), 410–414 (2006).
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol.1(5), 398–401 (2000).
   PubMed Web of Science ®Google Scholar
• Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol.75(22), 10730–10737 (2001).
   PubMed Web of Science ®Google Scholar
• Haeberle HA, Takizawa R, Casola A et al. Respiratory syncytial virus-induced activation of nuclear factor-κB in the lung involves alveolar macrophages and Toll-like receptor 4-dependent pathways. J. Infect. Dis.186(9), 1199–1206 (2002).
   PubMed Web of Science ®Google Scholar
• Awomoyi AA, Rallabhandi P, Pollin TI et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J. Immunol.179(5), 3171–3177 (2007).
   PubMed Web of Science ®Google Scholar
• Tal G, Mandelberg A, Dalal I et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis.189(11), 2057–2063 (2004).
   PubMed Web of Science ®Google Scholar
• Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet.25(2), 187–191 (2000).
   PubMed Web of Science ®Google Scholar
• Mandelberg A, Tal G, Naugolny L et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncytial virus bronchiolitis. Clin. Exp. Immunol.144(1), 48–52 (2006).
   PubMed Web of Science ®Google Scholar
• Puthothu B, Forster J, Heinzmann A, Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis. Markers22(5–6), 303–308 (2006).
   PubMed Web of Science ®Google Scholar
• Tulic MK, Hurrelbrink RJ, Prele CM et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J. Immunol.179(1), 132–140 (2007).
   PubMed Web of Science ®Google Scholar
• Fuentes S, Tran KC, Luthra P, Teng MN, He B. Function of the respiratory syncytial virus small hydrophobic protein. J. Virol.81(15), 8361–8366 (2007).
   PubMed Web of Science ®Google Scholar
• Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Prot. Sci.17(5), 813–820 (2008).
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med.357(19), 1903–1915 (2007).
   PubMed Web of Science ®Google Scholar
• Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med.9(9), 1131–1137 (2003).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J. Med. Virol.78(11), 1493–1497 (2006).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med.352(17), 1749–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis.190(2), 373–378 (2004).
   PubMed Web of Science ®Google Scholar
• Graham BS, Bunton LA, Wright PF, Karzon DT. Reinfection of mice with respiratory syncytial virus. J. Med. Virol.34(1), 7–13 (1991).
   PubMed Web of Science ®Google Scholar
• Graham BS, Bunton LA, Rowland J, Wright PF, Karzon DT. Respiratory syncytial virus infection in anti-µ-treated mice. J. Virol.65(9), 4936–4942 (1991).
   PubMed Web of Science ®Google Scholar
• Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol.20(1), 108–119 (2007).
   PubMed Web of Science ®Google Scholar
• Singleton R, Etchart N, Hou S, Hyland L. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J. Virol.77(21), 11303–11311 (2003).
   PubMed Web of Science ®Google Scholar
• Valosky J, Hishiki H, Zaoutis TE, Coffin SE. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus. Clin. Diagn. Lab. Immunol.12(1), 171–179 (2005).
   PubMedGoogle Scholar
• Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob. Agents Chemother.38(12), 2785–2791 (1994).
   PubMed Web of Science ®Google Scholar
• Fisher RG, Crowe JE Jr, Johnson TR, Tang YW, Graham BS. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. J. Infect. Dis.180(4), 1324–1327 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Age-related differences in humoral immune response to respiratory syncytial virus infection in adults. J. Med. Virol.73(2), 295–299 (2004).
   PubMed Web of Science ®Google Scholar
• Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J. Virol.61(6), 1851–1854 (1987).
   PubMed Web of Science ®Google Scholar
• Siber GR, Leombruno D, Leszczynski J et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis.169(6), 1368–1373 (1994).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J. Infect. Dis.177(2), 463–466 (1998).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis.189(2), 233–238 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR, Sullender WM. Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J. Gen. Virol.79(Pt 3), 479–487 (1998).
   PubMed Web of Science ®Google Scholar
• Zhao X, Liu E, Chen FP, Sullender WM. In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J. Virol.80(23), 11651–11657 (2006).
   PubMed Web of Science ®Google Scholar
• Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med.315(2), 77–81 (1986).
   PubMed Web of Science ®Google Scholar
• Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J. Pediatr.96(2), 179–186 (1980).
   PubMedGoogle Scholar
• Welliver TP, Garofalo RP, Hosakote Y et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J. Infect. Dis.195(8), 1126–1136 (2007).
   PubMed Web of Science ®Google Scholar
• Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of γ interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol.82(5), 2196–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Chang J, Srikiatkhachorn A, Braciale TJ. Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection. J. Immunol.167(8), 4254–4260 (2001).
   PubMed Web of Science ®Google Scholar
• Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J. Immunol.165(11), 6487–6495 (2000).
   PubMed Web of Science ®Google Scholar
• Tripp RA, Hou S, Etchart N et al. CD4(+) T cell frequencies and Th1/Th2 cytokine patterns expressed in the acute and memory response to respiratory syncytial virus I-E(d)-restricted peptides. Cell. Immunol.207(1), 59–71 (2001).
   PubMed Web of Science ®Google Scholar
• Durbin JE, Johnson TR, Durbin RK et al. The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol.168(6), 2944–2952 (2002).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Chang W, Braciale TJ. Induction of Th1 and Th2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol.73(8), 6590–6597 (1999).
   PubMed Web of Science ®Google Scholar
• Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, LaPierre NA. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. J. Med. Virol.70(2), 301–308 (2003).
   PubMed Web of Science ®Google Scholar
• Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J. Immunol.180(4), 2376–2384 (2008).
   PubMed Web of Science ®Google Scholar
• Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol.179(8), 5415–5424 (2007).
   PubMed Web of Science ®Google Scholar
• Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity15(4), 637–646 (2001).
   PubMed Web of Science ®Google Scholar
• Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol.65(3), 1634–1637 (1991).
   PubMed Web of Science ®Google Scholar
• Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol. Res.39(1–3), 225–239 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Varga SM, Braciale TJ, Graham BS. Vβ14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J. Virol.78(16), 8753–8760 (2004).
   PubMed Web of Science ®Google Scholar
• Alwan WH, Record FM, Openshaw PJ. CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin. Exp. Immunol.88(3), 527–536 (1992).
   PubMed Web of Science ®Google Scholar
• Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med.179(1), 81–89 (1994).
   PubMed Web of Science ®Google Scholar
• de Graaff PM, Heidema J, Poelen MC et al. HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology326(2), 220–230 (2004).
   PubMed Web of Science ®Google Scholar
• van Bleek GM, Poelen MC, van der Most R et al. Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. J. Virol.77(2), 980–988 (2003).
   PubMed Web of Science ®Google Scholar
• Levely ME, Bannow CA, Smith CW, Nicholas JA. Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J. Virol.65(7), 3789–3796 (1991).
   PubMed Web of Science ®Google Scholar
• de Bree GJ, Daniels H, Schilfgaarde M et al. Characterization of CD4+ memory T-cell responses directed against common respiratory pathogens in peripheral blood and lung. J. Infect. Dis.195(11), 1718–1725 (2007).
   PubMed Web of Science ®Google Scholar
• Lee FE, Walsh EE, Falsey AR et al. The balance between influenza- and RSV-specific CD4 T cells secreting IL-10 or IFNγ in young and healthy-elderly subjects. Mech. Ageing Dev.126(11), 1223–1229 (2005).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol.89(4), 405–421 (1969).
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol.89(4), 435–448 (1969).
   PubMed Web of Science ®Google Scholar
• Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol.89(4), 449–463 (1969).
   PubMed Web of Science ®Google Scholar
• Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol.4(4), 493–500 (1992).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J. Virol.72(4), 2871–2880 (1998).
   PubMed Web of Science ®Google Scholar
• Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol.31(9), 2566–2573 (2001).
   PubMed Web of Science ®Google Scholar
• Connors M, Kulkarni AB, Firestone CY et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J. Virol.66(12), 7444–7451 (1992).
   PubMed Web of Science ®Google Scholar
• Walzl G, Matthews S, Kendall S et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J. Exp. Med.193(7), 785–792 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J. Immunol.170(4), 2037–2045 (2003).
   PubMed Web of Science ®Google Scholar
• Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, de Swart RL, Osterhaus AD. HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J. Virol.74(21), 10240–10244 (2000).
   PubMed Web of Science ®Google Scholar
• Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD. Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J. Virol.74(16), 7694–7697 (2000).
   PubMed Web of Science ®Google Scholar
• Rock MT, Crowe JE Jr. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology108(4), 474–480 (2003).
   PubMed Web of Science ®Google Scholar
• Venter M, Rock M, Puren AJ, Tiemessen CT, Crowe JE Jr. Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. J. Virol.77(13), 7319–7329 (2003).
   PubMed Web of Science ®Google Scholar
• Heidema J, de Bree GJ, De Graaff PM et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J. Gen. Virol.85(Pt 8), 2365–2374 (2004).
   PubMed Web of Science ®Google Scholar
• Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW. Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J. Gen. Virol.83(Pt 2), 429–438 (2002).
   Google Scholar
• Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA. HLA-restricted CD8+ cytotoxic T lymphocyte, interferon-γ, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J. Infect. Dis.183(5), 687–696 (2001).
   PubMed Web of Science ®Google Scholar
• Heidema J, Lukens MV, van Maren WW et al. CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections. J. Immunol.179(12), 8410–8417 (2007).
   PubMed Web of Science ®Google Scholar
• Kulkarni AB, Collins PL, Bacik I et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J. Virol.69(2), 1261–1264 (1995).
   PubMed Web of Science ®Google Scholar
• Lukens MV, Claassen EA, de Graaff PM et al. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology352(1), 157–168 (2006).
   PubMed Web of Science ®Google Scholar
• Rutigliano JA, Rock MT, Johnson AK, Crowe JE Jr, Graham BS. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology337(2), 335–343 (2005).
   PubMed Web of Science ®Google Scholar
• Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat. Med.8(1), 54–60 (2002).
   PubMed Web of Science ®Google Scholar
• Connors M, Kulkarni AB, Collins PL et al. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol.66(2), 1277–1281 (1992).
   PubMed Web of Science ®Google Scholar
• Lee S, Miller SA, Wright DW, Rock MT, Crowe JE Jr. Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. J. Virol.81(5), 2349–2358 (2007).
   PubMed Web of Science ®Google Scholar
• Voges B, Vallbracht S, Zimmer G et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cell. Immunol.247(2), 85–94 (2007).
   PubMed Web of Science ®Google Scholar
• Ostler T, Davidson W, Ehl S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur. J. Immunol.32(8), 2117–2123 (2002).
   PubMed Web of Science ®Google Scholar
• Rutigliano JA, Graham BS. Prolonged production of TNF-α exacerbates illness during respiratory syncytial virus infection. J. Immunol.173(5), 3408–3417 (2004).
   PubMed Web of Science ®Google Scholar
• Simmons CP, Hussell T, Sparer T, Walzl G, Openshaw P, Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J. Immunol.166(2), 1106–1113 (2001).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J. Virol.78(11), 6024–6032 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J. Virol.73(10), 8485–8495 (1999).
   PubMed Web of Science ®Google Scholar
• Boelen A, Andeweg A, Kwakkel J et al. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine19(7–8), 982–991 (2000).
   PubMed Web of Science ®Google Scholar
• Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol.70(5), 2852–2860 (1996).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Braciale TJ. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med.186(3), 421–432 (1997).
   PubMed Web of Science ®Google Scholar
• Hussell T, Baldwin CJ, O’Garra A, Openshaw PJ. CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur. J. Immunol.27(12), 3341–3349 (1997).
   PubMed Web of Science ®Google Scholar
• Monick MM, Powers LS, Hassan I et al. Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J. Immunol.179(3), 1648–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Culley FJ, Pennycook AM, Tregoning JS, Hussell T, Openshaw PJ. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J. Virol.80(9), 4521–4527 (2006).
   PubMed Web of Science ®Google Scholar
• Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J. Virol.79(4), 2050–2057 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J. Leukoc. Biol. (2008).
   Google Scholar
• Haeberle HA, Kuziel WA, Dieterich HJ, Casola A, Gatalica Z, Garofalo RP. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1a in lung pathology. J. Virol.75(2), 878–890 (2001).
   PubMed Web of Science ®Google Scholar
• Haeberle HA, Casola A, Gatalica Z et al. IkB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection. J. Virol.78(5), 2232–2241 (2004).
   PubMed Web of Science ®Google Scholar
• Pribul PK, Harker J, Wang B et al. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J. Virol.82(9), 4441–4448 (2008).
   PubMed Web of Science ®Google Scholar
• Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8+ T cell efficacy. Eur. J. Immunol.38(8), 2168–2179 (2008).
   PubMed Web of Science ®Google Scholar
• Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J. Infect. Dis.161(3), 402–406 (1990).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J. Infect. Dis.183(1), 16–22 (2001).
   PubMed Web of Science ®Google Scholar
• Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med.161(5), 1501–1507 (2000).
   PubMed Web of Science ®Google Scholar
• Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJ. Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur. Respir. J.20(2), 376–382 (2002).
   PubMed Web of Science ®Google Scholar
• Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr. Infect. Dis. J.22(2 Suppl.), S58–S64 (2003).
   PubMed Web of Science ®Google Scholar
• Roman M, Calhoun WJ, Hinton KL et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am. J. Respir. Crit. Care Med.156(1), 190–195 (1997).
   PubMed Web of Science ®Google Scholar
• Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J. Exp. Med.196(10), 1381–1386 (2002).
   PubMed Web of Science ®Google Scholar
• Goriely S, Vincart B, Stordeur P et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J. Immunol.166(3), 2141–2146 (2001).
   PubMed Web of Science ®Google Scholar
• Hunt DW, Huppertz HI, Jiang HJ, Petty RE. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood84(12), 4333–4343 (1994).
   PubMed Web of Science ®Google Scholar
• Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin. Exp. Immunol.128(1), 118–123 (2002).
   PubMed Web of Science ®Google Scholar
• Siegrist CA. Neonatal and early life vaccinology. Vaccine19(25–26), 3331–3346 (2001).
   PubMed Web of Science ®Google Scholar
• Jonsdottir I. Maturation of mucosal immune responses and influence of maternal antibodies. J. Comp. Pathol.137(Suppl. 1), S20–S26 (2007).
   PubMed Web of Science ®Google Scholar
• Brandenburg AH, Groen J, van Steensel-Moll HA et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J. Med. Virol.52(1), 97–104 (1997).
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S. Effect of maternal antibody on IgA antibody response in nasopharyngeal secretion in infants and children during primary respiratory syncytial virus infection. J. Gen. Virol.75(Pt 8), 2115–2119 (1994).
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Tsutsumi H, Matsuda K, Nagai K, Ogra PL, Chiba S. Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection. Clin. Diagn. Lab. Immunol.1(4), 469–472 (1994).
   PubMedGoogle Scholar
• Fuller H, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst. Rev.4, CD004883 (2006).
   Google Scholar
• The IMpact-RSV Study Group.Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics102(3), 531–537 (1998).
   PubMed Web of Science ®Google Scholar
• Venkatesh MP, Weisman LE. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev. Vaccines5(2), 261–268 (2006).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics102(5), 1211–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics112(6 Pt 1), 1447–1452 (2003).
   PubMed Web of Science ®Google Scholar
• Harkensee C, Brodlie M, Embleton ND, McKean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J. Infect.52(1), 2–8 (2006).
   PubMed Web of Science ®Google Scholar
• Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis.163(4), 693–698 (1991).
   PubMed Web of Science ®Google Scholar
• Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory syncytial virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Engl. J. Med.300(10), 530–534 (1979).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. Drugs Aging22(7), 577–587 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Ely KH, Roberts AD, Kohlmeier JE, Blackman MA, Woodland DL. Aging and CD8+ T cell immunity to respiratory virus infections. Exp. Gerontol.42(5), 427–431 (2007).
   PubMed Web of Science ®Google Scholar
• Linton PJ, Haynes L, Klinman NR, Swain SL. Antigen-independent changes in naive CD4 T cells with aging. J. Exp. Med.184(5), 1891–1900 (1996).
   PubMed Web of Science ®Google Scholar
• Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common κ chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J. Exp. Med.190(7), 1013–1024 (1999).
   PubMed Web of Science ®Google Scholar
• Miller RA. The aging immune system: primer and prospectus. Science273(5271), 70–74 (1996).
   PubMed Web of Science ®Google Scholar
• Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J. Clin. Microbiol.27(12), 2666–2671 (1989).
   PubMed Web of Science ®Google Scholar
• Powers DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J. Infect. Dis.167(3), 584–592 (1993).
   PubMed Web of Science ®Google Scholar
• Powers DC. Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age. J. Am. Geriatr. Soc.41(1), 1–5 (1993).
   PubMed Web of Science ®Google Scholar
• Naylor K, Li G, Vallejo AN et al. The influence of age on T cell generation and TCR diversity. J. Immunol.174(11), 7446–7452 (2005).
   PubMed Web of Science ®Google Scholar
• Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med.205(3), 711–723 (2008).
   PubMed Web of Science ®Google Scholar
• Ely KH, Ahmed M, Kohlmeier JE et al. Antigen-specific CD8+ T cell clonal expansions develop from memory T cell pools established by acute respiratory virus infections. J. Immunol.179(6), 3535–3542 (2007).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE, Looney RJ et al. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J. Med. Virol.59(2), 221–226 (1999).
   PubMed Web of Science ®Google Scholar
• de Bree GJ, Heidema J, van Leeuwen EM et al. Respiratory syncytial virus-specific CD8+ memory T cell responses in elderly persons. J. Infect. Dis.191(10), 1710–1718 (2005).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Falsey AR, Walsh E, Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis.185(5), 682–685 (2002).
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Yim KC, Kuhn KH et al. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J. Infect. Dis.195(4), 511–518 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Gilmore X, Xu K, Wyde PR, Mbawuike IN. An aged mouse model for RSV infection and diminished CD8+ CTL responses. Exp. Biol. Med. (Maywood)227(2), 133–140 (2002).
   PubMed Web of Science ®Google Scholar
• Liu B, Kimura Y. Local immune response to respiratory syncytial virus infection is diminished in senescence-accelerated mice. J. Gen. Virol.88(Pt 9), 2552–2558 (2007).
   PubMed Web of Science ®Google Scholar
• Connors M, Collins PL, Firestone CY et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia – RSV recombinants or RSV. Vaccine10(7), 475–484 (1992).
   PubMed Web of Science ®Google Scholar
• Zeng RH, Gong W, Fan CF, Wang YF, Mei XG. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope. Vaccine24(7), 941–947 (2006).
   PubMed Web of Science ®Google Scholar
• Zeng R, Qi X, Gong W et al. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2. Vaccine25(42), 7422–7428 (2007).
   PubMed Web of Science ®Google Scholar
• Pinkenburg O, Vogelmeier C, Bossow S et al. Recombinant Sendai virus for efficient gene transfer to human airway epithelium. Exp. Lung Res.30(2), 83–96 (2004).
   PubMed Web of Science ®Google Scholar
• Ishida N, Homma M. Sendai virus. Adv. Virus Res.23, 349–383 (1978).
   PubMedGoogle Scholar
• Takimoto T, Hurwitz JL, Coleclough C et al. Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J. Virol.78(11), 6043–6047 (2004).
   PubMed Web of Science ®Google Scholar
• Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine18(5–6), 392–397 (1999).
   PubMed Web of Science ®Google Scholar
• van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev. Med. Virol.17(1), 5–34 (2007).
   PubMed Web of Science ®Google Scholar
• Xiang Z, Li Y, Gao G, Wilson JM, Ertl HC. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J. Immunol.171(8), 4287–4293 (2003).
   PubMed Web of Science ®Google Scholar
• Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J. Virol.82(5), 2350–2357 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu KH, Lubeck MD, Davis AR et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect. Dis.166(4), 769–775 (1992).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther.10(1), 46–55 (2008).
   PubMedGoogle Scholar
• Martinez-Sobrido L, Gitiban N, Fernandez-Sesma A et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol.80(3), 1130–1139 (2006).
   PubMed Web of Science ®Google Scholar
• Wright PF, Belshe RB, Kim HW, Van Voris LP, Chanock RM. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun.37(1), 397–400 (1982).
   PubMed Web of Science ®Google Scholar
• Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT. Evaluation of a live attenuated respiratory syncytial virus vaccine in infants. J. Pediatr.88(6), 931–936 (1976).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Crowe JE Jr et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. J. Infect. Dis.176(6), 1428–1436 (1997).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis.182(5), 1331–1342 (2000).
   PubMed Web of Science ®Google Scholar
• Karron RA, Buonagurio DA, Georgiu AF et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro : clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl Acad. Sci. USA94(25), 13961–13966 (1997).
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Belshe RB et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis.191(7), 1093–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl Acad. Sci. USA96(20), 11259–11264 (1999).
   PubMed Web of Science ®Google Scholar
• Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. Recombinant respiratory syncytial viruses with deletions in the NS1 , NS2 , SH , and M2-2 genes are attenuated in vitro and in vivo . Virology273(1), 210–218 (2000).
   PubMed Web of Science ®Google Scholar
• Wright PF, Karron RA, Belshe RB et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine25(42), 7372–7378 (2007).
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA282(15), 1440–1446 (1999).
   PubMed Web of Science ®Google Scholar
• Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med.163(3 Pt 2), S2–S6 (2001).
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL. Newly generated CD4 T cells in aged animals do not exhibit age-related defects in response to antigen. J. Exp. Med.201(6), 845–851 (2005).
   PubMed Web of Science ®Google Scholar